Transdermal delivery of methotrexate using mixed grades of Eudragit: Physico-chemical, in-vitro, and in-vivo evaluations

Clinical Research and Regulatory Affairs

Volumn 25, Issue 2, 2008, Pages 53-72

  Chandak, Ashok R ^a   Verma, Priya Ranjan Prasad ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Cygnus' Sandwich Patch Holder; In Vitro and In Vivo Evaluation; Interaction Studies; Methotrexate Patches; Transdermal Drug Delivery

Indexed keywords

EUDRAGIT; METHOTREXATE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; NONHUMAN; PHYSICAL CHEMISTRY; X RAY DIFFRACTION;

EID: 45949100811     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1080/10601330801937544     Document Type: Article

References (28)

1. Monkhouse DC, & Haq AS. Transdermal drug delivery-problems and promises. Drug Dev Ind Pharm. 1988;14:183-209.
2. Brown MB, Martin GP, Jones SA, & Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Del. 2006;13:175-187.
3. Kurihara-BT, Good WR, Feusullin S, & Signor C. Skin compatibility of transdermal drug delivery system. J Control Release. 1991;15:271-278.
4. Chandak AR, & Verma PRP. Formulation and characterization of eudragit based methotrexate transdermal delivery system. National Symposium on Controlled Release in Infection and Cancer, CRS (Indian Chapter), CDRI, Lucknow, India; June 18, 2007.
5. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57:163-172.
6. Dollery, C. Therapeutic Drugs. Vol. 2. 2d ed. Edinburgh: Churchill Livingstone; 1999: M90-M96.
7. Chartterjee DJ, Li WY, & Koda RT. Effect of vehicles and penetration enhancers on the in-vitro and in-vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm Res. 1997;14:1058-1065.
8. Anderson SE, Johansson L-H, Lexmuller K, Ekstrom GM. Anti-arthritic effect of methotrexate: is it really mediated by adenosine? Euro J Pharm Sci. 2000;9:333-343.
9. Hikima T, Tojo K, & Maibach HI. Skin metabolism in transdermal therapeutic systems. Skin Pharmacol Physiol. 2005;18:153-159.
10. Verma PRP, & Iyer SS. Transdermal delivery of propranolol using mixed grades of eudragit: design and in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2000;26:471-476.
11. Murthy TEGK, & Verma PRP. Controlled transdermal delivery of flurbiprofen films using mixed grades of eudragit: design, in-vitro and in-vivo evaluation. Int J Pharm Adv. 1996;1:391-397.
12. Kotiyan PN, & Vavia PR. Eudragit: role as crystallization inhibitors in drug-in-adhesive transdermal system of estradiol. Eur J Pharm Biopharm. 1993;52:173-180.
13. Iyer BV, Vasavada RC. Evaluation of lanolin alcohol films and kinetics of triamcinolone acetonide release. J Pharm Sci. 1979;68:782-787.
14. Verma PRP, & Iyer SS. Controlled transdermal delivery of propanolol using HPMC matrices: design, in-vitro and in-vivo evaluation. J Pharm Pharmacol. 2000;52:151-156.
15. Verma PRP, & Murthy TEGK. Transdermal flurbiprofen delivery using HPMC matrices: design, in-vitro and in-vivo evaluation. Drug Dev Ind Pharm. 1997;23:633-638.
16. Verma PRP, & Patel, RK. Verapamil releasing transdermal drug delivery using HPMC matrices: design in-vitro and in-vivo evaluation. Pharm Sci. 1996;2:461-465.
17. Man M, Chang C, Lee PH, Broman CT, & Cleary GW. New improved paddle method for determining the in-vitro drug release profiles of transdermal delivery systems. J Control Rel. 1993;27:59-68.
18. Mansilla AE, Meras ID, Madera AZ, Pedano L, Ferreyra C. Kinetic fluorimetric determination of the antineoplastic methotrexate (MTX) in human serum. J Pharm Biomed Ana. 2002;29:851-858.
19. Chamberlin AR, Cheung APK, Lim P. Methotrexate. In: Florey K, ed. Analytical Profiles of Drug Substances. Vol. 5. London, New York, San Francisco: Academic Press Inc; 1976:283-305.
20. Moffat AC. Methotrexate. In: Clarke's Isolation and Identification of Drugs: In Pharmaceuticals, Body Fluids, and Post-mortem Material. 2nd ed. London: Pharmaceutical Press; 1986:756.
21. Wartewig S, & Neubert RHH. Pharmaceutical application of mid-IR and Raman spectroscopy. Adv Drug Del Rev. 2005;57:1144-1170.
22. Verma PRP, & Patel RK. Transdermal drug delivery of verapamil using mixed grades of eudragit: design, in-vitro and in-vivo evaluation. Pharm Sci. 1996;2:269-273.
23. Varshosaz J, Faghihian H, & Rastgoo K. Preparation and characterization of metoprolol controlled-release solid dispersions. Drug Del. 2006;13:295-302.
24. Korsmeyer RW, Gurny R, Doelker E, Buri P, & Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25-35.
25. Perioli L, Ambrogi V, Rubini D, Giovagnoli S, Ricci M, Blasi P, & Rossi C. Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. J Control Rel. 2004;95:521-533.
26. Rohr UD, Altenburger R, & Kissel T. Pharmacokinetics of the transdermal reservoir membrane system delivering β-estradiol: in-vitro/in-vivo correlation. Pharm Res. 1998;15:877-882.
27. Mutalik S, & Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci. 2004;93:1577-1594.
28. McClave JT, & Benson PG. Statistics for Business and Economics. 4th ed. London & San Francisco: Maxwell and Macmillan International Editions; 1990:945-1002.